GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (LTS:0KC7) » Definitions » Total Liabilities

OncoSec Medical (LTS:0KC7) Total Liabilities : $14.36 Mil (As of Jan. 2023)


View and export this data going back to 2018. Start your Free Trial

What is OncoSec Medical Total Liabilities?

OncoSec Medical's Total Liabilities for the quarter that ended in Jan. 2023 was $14.36 Mil.

OncoSec Medical's quarterly Total Liabilities declined from Jul. 2022 ($15.76 Mil) to Oct. 2022 ($15.42 Mil) and declined from Oct. 2022 ($15.42 Mil) to Jan. 2023 ($14.36 Mil).

OncoSec Medical's annual Total Liabilities increased from Jul. 2020 ($16.03 Mil) to Jul. 2021 ($18.20 Mil) but then declined from Jul. 2021 ($18.20 Mil) to Jul. 2022 ($15.76 Mil).


OncoSec Medical Total Liabilities Historical Data

The historical data trend for OncoSec Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Total Liabilities Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.32 5.61 16.03 18.20 15.76

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.27 14.11 15.76 15.42 14.36

OncoSec Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OncoSec Medical's Total Liabilities for the fiscal year that ended in Jul. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.633+(4.127+5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=15.76

Total Liabilities=Total Assets (A: Jul. 2022 )-Total Equity (A: Jul. 2022 )
=21.878-6.118
=15.76

OncoSec Medical's Total Liabilities for the quarter that ended in Jan. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.231+(2.127+5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=14.36

Total Liabilities=Total Assets (Q: Jan. 2023 )-Total Equity (Q: Jan. 2023 )
=8.871--5.486
=14.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (LTS:0KC7) Business Description

Traded in Other Exchanges
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (LTS:0KC7) Headlines

No Headlines